Overview

Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema

Status:
Completed

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

This study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or as monotherapy in Asian patients with visual impairment due to Diabetic Macular Edema (DME).

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Ranibizumab